San Antonio Breast Cancer Symposium (SABCS) Activities and Abstracts

**Educational Sessions: December 10th**

2:00 PM – 3:30 PM  
**Location:** Stars at Night Ballroom 1 - 3rd Level  
*Assessment of PD-L1 in breast cancer to predict response to immunotherapy*  
David Rimm

**Poster Sessions: December 11th 5:00 PM - 7:00 PM**

**Location:** Stars at Night Ballroom 1&2  
*Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)*  
Lajos Pusztai, Emily Reisenbichler, Yailai Bai, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Brigid Killelea, Anees Chagpar, Courtney Frederick, Trisha Burello, Kim Blenman, David Rimm, and Andrea Silber

**Location:** Hall 1  
*Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy*  
Mariya Rozenblit, Lajos Pusztai, Kerin Adelson, and Sarah Mougalian

**Poster Sessions: December 12th 7:00 AM - 9:00 AM**

**Location:** Hall 1  
*Treatment patterns and costs of metastatic triple negative breast cancer (mTNBC) in US women: A retrospective cohort study of first-line chemotherapy*  
Sarah Mougalian
Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer
Erin Hofstatter, Morgan Levine, Zuyun Liu, Tess O’Meara, Disha Dalela, and Lajos Pusztai

Location: Hall 1

Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays in triple negative breast cancer
Emily Suzanne Reisenbichler, Vasiliki Pelekanou, Vesal Yaghoobi, Fahad Ahmed, Kimberly Cole, Lajos Pusztai, and David Rimm

Poster Sessions: December 12th 5:00 PM - 7:00 PM

Location: Hall 1

The impact of obesity to promote breast tumor growth is attenuated in vivo in mice by reversing hyperinsulinemia
Ali Nasiri, Zongyu Li, Brooks Leitner, and Rachel Perry

An open source, automated tumor infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancer
Yalai Bai, Jon Zugazagoitia, Sandra Martinez-Morilla, Fahad Shabbir Ahmed, and David Rimm

Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC)
Kim Blenman, Xiaotong Li, Michal Marczyk, Tess O’Meara, Vesal Yaghoobi, Vignesh Gunasekharan, Tristen Park, David Rimm, and Lajos Pusztai

Poster Sessions: December 13th 7:00 AM - 9:00 AM

Location: Stars at Night Ballroom 3&4

A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts
Patricia LoRusso
Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer
Annette Hood, Shi-Yi Wang, Sarah Mougalian, Michael DiGiovanna, Kerin Adelson, and Lajos Pusztai

Location: Hall 1

Quantitative assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer (TNBC)
Fahad Shabbir Ahmed, John McGuire, Patricia Gaule, Kim Blenman, Lajos Pusztai, and David Rimm

Poster Sessions: December 13th 5:00 PM - 7:00 PM

Location: Hall 1

Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study
Balazs Acs and David Rimm

Development and validation of the “radiotherapy for older women” risk calculator
Shi-Yi Wang, Sarah Mougalian, Brigid Killelea, Jeph Herrin, Liana Fraenkel, Cary Gross, and Suzanne Evans

Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)
Michal Marczyk, Erin Hofstatter, Tara Sanft, Andrea Silber, Michael DiGiovanna, Daniel Zelterman, Lajos Puzstai, and Christos Hatzis

Poster Sessions: December 14th 7:00 AM - 9:00 AM

Location: Hall 1

My PROfile: A web-based tool to assess patient reported outcomes (PROs) in women with metastatic breast cancer (MBC): Preliminary results
Sarah Mougalian, Maureen Canavan, Renee Capasso, Jenerius Aminawung, and Cary Gross

Cost-effectiveness of endocrine therapy or radiation treatment alone or in combination for standard- and good-risk DCIS
James Yu and Shiyi Wang